{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:49:30Z","timestamp":1778262570370,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007037","name":"Ministeriet Sundhed Forebyggelse","doi-asserted-by":"publisher","award":["28\/1\\u20132021"],"award-info":[{"award-number":["28\/1\\u20132021"]}],"id":[{"id":"10.13039\/501100007037","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007037","name":"Ministeriet Sundhed Forebyggelse","doi-asserted-by":"publisher","award":["3\/6\\u20132021"],"award-info":[{"award-number":["3\/6\\u20132021"]}],"id":[{"id":"10.13039\/501100007037","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.vaccine.2025.128155","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T13:01:26Z","timestamp":1766494886000},"page":"128155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Immunogenicity of SARS-CoV-2 primary vaccination and boosters in patients with immune-mediated inflammatory diseases: Impact of immunosuppressive therapy"],"prefix":"10.1016","volume":"73","author":[{"given":"Fredrikke Dam","family":"Larsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Karina","family":"Juhl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa Loks\u00f8","family":"Dietz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina Breinholt","family":"St\u00e6rke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isik Somuncu","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lothar","family":"Wiese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Benfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Bodilsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vibeke","family":"Klastrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan Olaf","family":"Lindvig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Line Dahlerup","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene Surland","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Tolstrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars J\u00f8rgen","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole Schmeltz","family":"S\u00f8gaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten Schade","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.vaccine.2025.128155_bb0015","doi-asserted-by":"crossref","first-page":"E206","DOI":"10.1093\/cid\/ciaa1012","article-title":"Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network (COVID-NET)","volume":"72","author":"Kim","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128155_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004086","article-title":"Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study","volume":"20","author":"Turtle","year":"2023","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2025.128155_bb0025","first-page":"35","article-title":"Impact of COVID-19 on immunocompromised populations during the omicron era: insights from the observational population-based INFORM study","author":"Evans","year":"2023","journal-title":"The lancet regional health - Europe."},{"issue":"7","key":"10.1016\/j.vaccine.2025.128155_bb0030","doi-asserted-by":"crossref","first-page":"e490","DOI":"10.1016\/S2665-9913(22)00098-4","article-title":"Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform","volume":"4","author":"MacKenna","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.vaccine.2025.128155_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103358","article-title":"Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: a systematic review and meta-analysis","volume":"57","author":"Schiavetti","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"10.1016\/j.vaccine.2025.128155_bb0040","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2665-9913(21)00247-2","article-title":"COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses","volume":"3","author":"Fagni","year":"2021","journal-title":"Lancet Rheumatol."},{"issue":"6","key":"10.1016\/j.vaccine.2025.128155_bb0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.19766","article-title":"Association between anti-CD20 therapies and COVID-19 severity among patients with relapsing-remitting and progressive multiple sclerosis","volume":"6","author":"Januel","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.vaccine.2025.128155_bb0050","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s10067-020-04996-7","article-title":"Effects of rituximab therapy on B cell differentiation and depletion","volume":"39","author":"Bergantini","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.vaccine.2025.128155_bb0055","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/ard.55.4.237","article-title":"Divergent effects of methotrexate on the clonal growth of T and B lymphocytes and synovial adherent cells from patients with rheumatoid arthritis","volume":"55","author":"Nakajima","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2025.128155_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00676","article-title":"Etanercept inhibits B cell differentiation by regulating TNFRII\/TRAF2\/NF-\u03baB Signaling pathway in rheumatoid arthritis","volume":"11","author":"Cai","year":"2020","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128155_bb0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of Oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.vaccine.2025.128155_bb0070","author":"EMA"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128155_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102927","article-title":"Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis","volume":"21","author":"Jena","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.vaccine.2025.128155_bb0080","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.cgh.2022.02.030","article-title":"Effectiveness and durability of COVID-19 vaccination in 9447 patients with IBD: a systematic review and Meta-analysis","volume":"20","author":"Jena","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.vaccine.2025.128155_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(21)00251-4","article-title":"Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-Centre, open-label study","volume":"3","author":"Moor","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128155_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002036","article-title":"Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients","volume":"8","author":"Schietzel","year":"2022","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128155_bb0095","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s13311-021-01165-9","article-title":"Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies","volume":"19","author":"Capone","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.vaccine.2025.128155_bb0100","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.3389\/fimmu.2021.781843","article-title":"Effect of different disease-modifying therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis patients","volume":"12","author":"Pitzalis","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128155_bb0105","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001847","article-title":"Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors","volume":"8","author":"Venerito","year":"2022","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128155_bb0110","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1053\/j.gastro.2021.10.029","article-title":"Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with anti-TNF\u03b1","volume":"162","author":"Edelman-Klapper","year":"2022","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.vaccine.2025.128155_bb0115","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease","volume":"80","author":"Haberman","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2025.128155_bb0120","article-title":"Glucocorticoids and fingolimodB Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2","author":"Deepak","year":"2025","journal-title":"medRxiv"},{"issue":"12","key":"10.1016\/j.vaccine.2025.128155_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-069065","article-title":"Cohort Profile:The Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 vaccines (ENFORCE)","volume":"12","author":"St\u00e6rke","year":"2022","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128155_bb0130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s43856-023-00277-x","article-title":"Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity","volume":"3","author":"Dietz","year":"2023","journal-title":"Commun Med"},{"key":"10.1016\/j.vaccine.2025.128155_bb0135","article-title":"Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines","volume":"9","author":"Hvidt","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"10.1016\/j.vaccine.2025.128155_bb0140","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.cmi.2022.03.003","article-title":"Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE study","volume":"28","author":"S\u00f8gaard","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"10.1016\/j.vaccine.2025.128155_bb0145","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3390\/vaccines9121470","article-title":"Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis","volume":"9","author":"Achtnichts","year":"2021","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128155_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002166","article-title":"Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy","volume":"8","author":"Sidler","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.vaccine.2025.128155_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104484","article-title":"Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators","volume":"70","author":"Sabatino","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"10.1016\/j.vaccine.2025.128155_bb0160","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1007\/s00415-022-11296-4","article-title":"Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod","volume":"269","author":"Capuano","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.vaccine.2025.128155_bb0165","doi-asserted-by":"crossref","first-page":"1432348","DOI":"10.3389\/fimmu.2024.1432348","article-title":"Humoral and cellular immune response from first to fourth SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients\u2014a longitudinal cohort study","volume":"15","author":"Novak","year":"2024","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2025.128155_bb0170","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1007\/s10238-023-01163-5","article-title":"Impact of methotrexate on humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis","volume":"23","author":"Shirata","year":"2023","journal-title":"Clin Exp Med"},{"issue":"6","key":"10.1016\/j.vaccine.2025.128155_bb0175","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1136\/annrheumdis-2021-221876","article-title":"Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases","volume":"81","author":"Arumahandi de Silva","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2025.128155_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2022.100479","article-title":"Seroprevalence and infection fatality rate of the SARS-CoV-2 omicron variant in Denmark: a nationwide serosurveillance study","volume":"21","author":"Erikstrup","year":"2022","journal-title":"The Lancet Regional Health - Europe"},{"issue":"7","key":"10.1016\/j.vaccine.2025.128155_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0281972","article-title":"Patterns of testing in the extensive Danish national SARS-CoV-2 test set-up","volume":"18","author":"Gram","year":"2023","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128155_bb0195","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001143","article-title":"Humoral and cellular responses to SARS-CoV-2 in convalescent COVID-19 patients with multiple sclerosis","volume":"9","author":"Zabalza","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.vaccine.2025.128155_bb0200","first-page":"14","article-title":"Negative SARS-CoV2-antibodies after positive COVID-19-PCR nasopharyngeal swab in patients treated with anti-CD20 therapies","author":"Friedli","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"10.1016\/j.vaccine.2025.128155_bb0205","volume":"26","author":"Baerends","year":"2023","journal-title":"SARS-CoV-2 vaccine-induced antibodies protect against Omicron breakthrough infection iScience"},{"key":"10.1016\/j.vaccine.2025.128155_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107111","article-title":"Development of antibody levels and subsequent decline in individuals with vaccine induced and hybrid immunity to SARS-CoV-2","volume":"146","author":"Reekie","year":"2024","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128155_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1146841","article-title":"Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections","volume":"14","author":"Egri","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.128155_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105317","article-title":"T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study","volume":"108","author":"Wolf","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2025.128155_bb0225","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.3389\/fimmu.2022.926318","article-title":"Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies","volume":"13","author":"Alfonso-Dunn","year":"2022","journal-title":"Front Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25014537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25014537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:22:40Z","timestamp":1777537360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25014537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":42,"alternative-id":["S0264410X25014537"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128155","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of SARS-CoV-2 primary vaccination and boosters in patients with immune-mediated inflammatory diseases: Impact of immunosuppressive therapy","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128155"}}